Peregrine Pharmaceuticals (now Avid Bioservices)
Peregrine was a Californian biotech whose phosphatidylserine antibody bavituximab failed a phase 3 lung cancer trial; the company kept its contract manufacturing arm and became Avid Bioservices.
Overview
Peregrine Pharmaceuticals, based in Tustin, California, developed bavituximab, an antibody against phosphatidylserine exposed on tumour blood vessels, and took it into the phase 3 SUNRISE trial in non-small cell lung cancer, which was stopped for futility in 2016. The company then concentrated on its contract development and manufacturing business and renamed itself Avid Bioservices in 2018. The bavituximab trials remain on ClinicalTrials.gov under the Peregrine name.
Similar pages
not linked directly; found by shared links- CompanyAgennix
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyTelik
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.